Johns Hopkins ABX Guide
Technivie
INDICATIONS
FDA
FDA
- Technivie has been discontinued in the U.S. and Canada.
- Technivie: combination pack of three medications, ombitasvir/paritaprevir/ritonavir. Indicated for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection without cirrhosis with or without the addition of ribavirin.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 12, 2022
Citation
Kilcrease, Christin, and Kathryn Dzintars. "Technivie." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540655/all/Technivie.
Kilcrease C, Dzintars K. Technivie. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540655/all/Technivie. Accessed December 6, 2023.
Kilcrease, C., & Dzintars, K. (2022). Technivie. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540655/all/Technivie
Kilcrease C, Dzintars K. Technivie [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2023 December 06]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540655/all/Technivie.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Technivie
ID - 540655
A1 - Kilcrease,Christin,Pharm.D.
AU - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2022/02/12/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540655/all/Technivie
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
